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CRISPR/Cas9 mediated generation 
of an ovine model for infantile 
neuronal ceroid lipofuscinosis 
(CLN1 disease)
S. L. Eaton1, C. Proudfoot1, S. G. Lillico1, P. Skehel2,3, R. A. Kline1, K. Hamer  5, 
N. M. Rzechorzek  4,5, E. Clutton6, R. Gregson6, T. King1, C. A. O’Neill7, J. D. Cooper8,9, 
G. Thompson2, C. B. Whitelaw1 & T. M. Wishart1,3
The neuronal ceroid lipofuscinoses (NCLs) are a group of devastating monogenetic lysosomal disorders 
that affect children and young adults with no cure or effective treatment currently available. One of the 
more severe infantile forms of the disease (INCL or CLN1 disease) is due to mutations in the palmitoyl-
protein thioesterase 1 (PPT1) gene and severely reduces the child’s lifespan to approximately 9 years of 
age. In order to better translate the human condition than is possible in mice, we sought to produce a 
large animal model employing CRISPR/Cas9 gene editing technology. Three PPT1 homozygote sheep 
were generated by insertion of a disease-causing PPT1 (R151X) human mutation into the orthologous 
sheep locus. This resulted in a morphological, anatomical and biochemical disease phenotype that 
closely resembles the human condition. The homozygous sheep were found to have significantly 
reduced PPT1 enzyme activity and accumulate autofluorescent storage material, as is observed in CLN1 
patients. Clinical signs included pronounced behavioral deficits as well as motor deficits and complete 
loss of vision, with a reduced lifespan of 17 ± 1 months at a humanely defined terminal endpoint. 
Magnetic resonance imaging (MRI) confirmed a significant decrease in motor cortical volume as well 
as increased ventricular volume corresponding with observed brain atrophy and a profound reduction 
in brain mass of 30% at necropsy, similar to alterations observed in human patients. In summary, we 
have generated the first CRISPR/Cas9 gene edited NCL model. This novel sheep model of CLN1 disease 
develops biochemical, gross morphological and in vivo brain alterations confirming the efficacy of the 
targeted modification and potential relevance to the human condition.
The neuronal ceroid lipofuscinoses (NCL) are a group of predominantly autosomal-recessive storage disorders 
which mainly affect children and young adults, and are notably the most common form of childhood dementia1. 
Children who suffer from this neurodegenerative condition experience psychological and motor deficits, loss 
of vision and seizures leading to a profound impact upon the CNS and ultimately a premature death. The age of 
onset and rate of disease progression are governed by which ‘CLN’ gene is deficient and the precise mutation that 
is present. Mutations in the CLN1/PPT1 gene are responsible for one of the most severe and early onset forms of 
the disease, with clinical onset between 12–24 months of age2. These children have a severely reduced lifespan, 
with death occurring at approximately 9 years of age3. Currently there is no cure for the disease.
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Diagnosis of INCL can be elusive, however there is a reliable blood test available that can be employed for pre 
and post-natal diagnosis4. This assay detects a significant reduction in the activity of the enzyme palmitoyl-protein 
thioesterase 1 (PPT1) in leucocytes from CLN1 patients, which is a direct consequence of mutations in the PPT1 
gene5. Many other disease-specific hallmarks exist; some are detectable with specialist imaging techniques whilst 
others are more readily seen at autopsy. These include, intracellular accumulation of autofluorescent storage mate-
rial and regional neuroanatomical alterations6.
In order to generate a model of the human condition and enable pre-symptomatic investigations for evalua-
tion of potential therapeutic interventions7, a PPT1 null mutant mouse model was produced8. These mice have 
been valuable for defining progressive neuropathological and behavioral changes, and for testing experimental 
therapies2. However, the extent of neurodegeneration in these mice, even at disease end stage9,10, does not reach 
the full devastating extent seen in human INCL. Larger animal species have advantages over mice as disease mod-
els, and two naturally occurring cases of CLN1 disease have also been reported in dogs - a male daschund with a 
unique mutation not previously reported in humans and one female cane corso with an alteration detected in 2 
human cases11,12 (NCL Mutation Database, http://www.ucl.ac.uk/ncl/). However, as far as we are aware, neither of 
these unique animals are currently available as models that can be studied. Naturally occurring ovine models of 
CLN5 and CLN6 forms of NCLs do exist and have proved valuable for studying the pathogenesis of these disor-
ders and the pre-clinical development of therapies including viral mediated gene transfer13–16.
In this study we have attempted to reproduce the complex nature of the disease seen in INCL patients by gen-
erating a large animal model that carries disease-causing mutations present in human CLN1 disease. We describe 
how the CRISPR/Cas9 system was used to introduce the commonly occurring human R151X mutation into the 
ovine PPT1 locus5,17. We then demonstrate that the downstream biochemical and regional morphological brain 
alterations commonly reported in human patients are present in this novel ovine model at a humanely defined 
disease endpoint. This is the first time that the CRISPR/Cas9 system has been used to generate a model of CLN1 
disease or similar lysosomal storage disorders. These novel CLN1 sheep will not only help further our under-
standing of INCL pathogenesis, but also have the potential to enable therapeutic development for this devastating 
pediatric disorder.
Results
Generation of PPT1 sheep. As homology DNA repair (HDR) is believed to be most efficient immedi-
ately proximal to a double strand DNA break (DSB), two alternative single stranded guide RNAs (sgRNAs) were 
designed as close as possible to the coding sequence for R151 of sheep PPT1 (Fig. 1A). The CCTop CRISPR/
Cas9 online tool (https://crispr.cos.uni-heidelberg.de/) predicts a low probability of off-target cutting by either of 
these guides within exonic sequence of the sheep genome. CRISPR reagents (sgRNA (MEGAshortscript T7 tran-
scription kit, Life Tech.) + ssODN (single strand Oligodioxynucleotide; IDT) + Cas9 mRNA (CRISPR Associated 
protein 9 mRNA; PNA Biosciences)) were microinjected into the cytoplasm of in vitro-derived sheep zygotes as 
previously described18, with no evidence of toxicity observed during subsequent culture. Sixty-six blastocysts 
were transferred to 33 hormonally synchronized recipient ewes18, with 19 (58%) carrying a pregnancy to term. 
Twenty-four lambs were genotyped by PCR of genomic DNA and sequencing (Fig. 1B), revealing 12 (50%) that 
were not edited, 3 (12.5%) had random insertions or deletions (indels) at the target locus, 6 (25%) had undergone 
HDR to introduce the stop codon at the target locus of a single allele and 3 (12.5%) had undergone HDR on both 
alleles (Table 1). All lambs were grossly phenotypically normal at birth.
Figure 1. CRISPR/Cas9 engineering of PPT1 sheep (A) sgRNAs were designed proximal to the PPT1 target 
site on Ovis aries chromosome 1 (indicated by blue arrow). (B) Sheep zygotes were injected with Cas9 mRNA, 
sgRNA1 or sgRNA2 and an HDR (homology directed repair) template (90mer ssODN).
Blastocysts Recipients Pregnancies Lambs
Genotypes
WT Indel
Het 
HDR
HOM 
HDR
sgRNA1 35 17 10 10 3 3 2 2
sgRNA2 31 16 19 14 9 0 4 1
Table 1. Editing the sheep PPT1 locus. Details of blastocysts, recipients, pregnancies and the geneotypes of 
liveborn offspring for each sgRNA. WT: wild type; Indel: insertion and/or deletion; Het HDR: heterozygous 
homology dependant repair; Hom HDR: homozygous homology dependent repair.
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Confirmation of CLN1 phenotype. A one step fluorometric PPT1 enzyme activity assay4 was employed in 
wild type, heterozygote and asymptomatic homozygote PPT1 sheep plasma at approximately 1 year of age (Fig. 2). 
There was a significant decrease in PPT1 enzyme activity in homozygous vs. heterozygote sheep (P = 0.0025) 
(Fig. 2), consistent with the near complete reduction in activity observed using this assay in the human patient 
population4. Another characteristic hallmark of CLN1 disease is the accumulation of autofluorescent storage 
material within lysosomes. This was also detected in the spinal cords of the homozygote sheep (Fig. 2).
Visual function was assessed via remote observation of navigation and visual tracking alongside menace 
response testing, whilst pupillary light and dazzle reflex testing was used to assess subcortical responses to light 
and glare, respectively16,19,20. By 12 ± 1 months of age, homozygote sheep were observed bumping into obstacles 
followed by a significant deficit in the menace response by 17 ± 1 months at the humanely defined endpoint 
(Supplementary Fig. 2). Motor performance and vestibular system integrity were assessed remotely by observa-
tion of gait and balance, followed by direct testing of conscious proprioception using hoof placement, knuckling 
and hopping tests, and balance via a ‘push test’20. There was a significant increase in proprioceptive deficit in the 
homozygote sheep (Supplementary Fig. 2).
Regional specific disease alterations are observed in PPT1 sheep brains. The homozygote sheep 
and WT controls were euthanised at 17 ± 1 months in accordance with home office specification when a moder-
ate phenotype was observed. Gross morphological assessment of the homozygote resected brains at post mortem 
showed a statistically significant 30% decrease in mass compared with age-matched wild type controls with pro-
nounced regional atrophy of the neocortex (Fig. 3A). Qualitative imaging assessment by MRI identified a global 
reduction in brain volumes, with enlarged ventricles, and thinned grey matter, particularly in sensory regions of 
the neocortex caudal to the central sulcus (Fig. 3B). The hindbrain, by comparison was relatively normal although 
there appeared to be some atrophy of the neocerebellum (Fig. 3B).
Quantitative Imaging analysis using MATLAB software allowed more detailed volumetric evaluation of spe-
cific regions of interest: the motor cortices, triventricular spaces and cerebellum (Fig. 3C). The volumetric anal-
yses of the homozygous sheep demonstrated significantly lower cerebral volume with an average 20% decrease 
at the time of imaging (Fig. 3D). The triventricular cerebral spinal fluid (CSF) space in the homozygotes was 
significantly increased on average by 50%, however these sheep had not developed clear differences in overall 
cerebellar volumes at this time point (Fig. 3D). Features in this model recapitulate the gross anatomical findings 
in a naturally occurring ovine model caused by mutation of the CLN6 gene21.
Discussion and Conclusions
Here we have shown for the first time that CRISPR/Cas 9 engineering can effectively produce a large mammalian 
model of childhood dementia by introducing a disease-causing mutation present in human cases. This new ovine 
model shows a regionally-selective pattern of neurodegeneration, and relevant clinical signs similar to those 
reported in human patients with INCL2. Taken together our data suggest a more robust recapitulation of human 
disease than is shown by the existing CLN1 mouse models. Certainly, even without detailed neuropathological 
assessment, the degree of cortical atrophy is much more pronounced than in PPT1 deficient mice9,10, perhaps due 
to disparities in rodent brain anatomy when compared to humans22. These CLN1 data resemble the much more 
pronounced extent of cortical pathology in CLN6 deficient sheep compared to nclf mice23,24.
By using CRISPR/Cas9 editing we have successfully incorporated the most common human disease-causing 
mutation in the gene, PPT1, resulting in development of clinical signs and a humanely defined endpoint of 
17 ± 1 months, approximately 10% of the lifespan of a wild type control sheep. This is comparable to the reduced 
lifespan of human INCL patients who on average die at 9 years of age, approximately 11% of the average human 
life expectancy25. By comparison the existing murine model reaches a terminal stage by 8 months which is 
approximately 33% of its potential life span8. Other principal phenotypic characteristics of the human disorder 
observed in this PPT1 sheep model include accumulations of autofluorescent material, visual impairment and 
brain region-specific volume alterations3. These CLN1 sheep have an overall difference in brain mass of 30% at 
Figure 2. Confirmation of CLN1 disease. (A) Asymptomatic homozygote PPT1 sheep. (B) PPT1 enzyme 
activity assay tested in plasma (20ug protein) detected significant differences between heterozygote and 
homozygote sheep (P = 0.0025). Statistical analyses utilized unpaired two-tailed Student’s t-test. Error 
bars represent the standard error of the mean (SEM). (C) Autofluoroscent inclusion bodies are detected in 
homozygote sheep scale bar represents 50 microns.
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necropsy. This again more closely resembles the severity of human disease2, compared to the reductions in brain 
mass observed in the murine model9.
MRI has been informative in following disease progression in INCL patients26. Our imaging data mirror 
those seen in a related naturally occurring CLN5 ovine model, and the dramatic impact of CLN1 disease upon 
the volume of the cerebral cortex27–29 with more subtle effects upon the cerebellum. The onset and progression of 
such regional effects upon the CLN1 sheep brain will be important to define, both via imaging and pathological 
studies, and these data will be very informative for the targeting of experimental therapies.
Many of the difficulties associated with neurodegenerative disease research (at the level of understanding 
disease progression and subsequent intervention development) have been attributed to the use of models that 
do not faithfully recapitulate the human condition30. Diseases that naturally occur in large animals are extremely 
useful for determining pathogenic events and drug discovery driven research16,31, and the pre-clinical work done 
in CLN2 deficient dachshunds prior to FDA approval of ERT exemplifies this31,32. However, with the advent of 
gene editing technologies we are no longer limited to identifying naturally occurring forms of genetic disease, 
which may not bear the same mutations seen in the patient population15. Thus, models can now be generated with 
increasing genetic specificity by recreating human disease-causing mutations33 as we have done for the first time 
in CLN1 disease sheep.
Such methods have already proven to be more effective in the development of two GM porcine models; 
Huntington disease and Ataxia telangiectasia (AT)34,35. These large animal models display disease phenotypes 
inadequately represented in commonly used murine systems for the same conditions. These include deficits in 
cerebellar cytoarchitecture detected at birth in the AT model, and a respiratory difficulty phenotype which is a 
secondary characteristic of human Huntington disease. Thus, although the financial burden of generating mod-
els in larger animal species is initially high, these models have considerable potential to substantially reduce the 
overall socioeconomic burden of such neurodegenerative disorders.
Figure 3. Selective pattern of neurodegeneration is observed in ovine model of INCL. (A) Gross anatomical 
disparity identified between WT control (left) and PPT1 homozygote (right) brains. Total fresh brain weight is 
significantly reduced in homozygote sheep shown in scatter plot (P = 0.0006). (B) Comparison of orthogonal 
T2-weighted spin echo imaging slices in example wild type (top row) and homozygous (bottom row) animals. 
There is global reduction in cerebral volume (red arrows), with ventriculomegaly (blue arrows) and thinning of 
the frontal cortex in the homozygote sheep. Note increased fluid signal between cerebellar folia (green arrows) 
suggestive of neocerebellar atrophy. (C) Volumetric renderings showing regions of interest for bilateral motor 
cortex (red), cerebellum (green), and tri-ventricular cerebrospinal fluid (blue). (D) Scatter plot with bar chart 
of volumetric data for the bilateral motor cortex, triventricular CSF and cerebellum with corresponding 3D 
images above each data point relating to the area and genotype. Statistical analyses utilized unpaired two-tailed 
Student’s t-test. Error bars represent SEM.
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Here we have shown that CLN1 disease sheep, created using CRISPR/cas9 technology to bear a mutation 
causing a human neurodegenerative disorder, recapitulates disease-specific hallmarks including clinical signs 
and morphological changes as determined by neuroimaging and gross pathology. Whilst our data from end-stage 
sheep are encouraging, future work including in depth neuropathological, molecular and MRI studies throughout 
the lifespan of affected animals will more fully define the validity of this novel model. These additional studies 
should permit earlier detection of divergence from normal brain development, and potentially yield more sen-
sitive and specific biomarkers for disease progression and landmarks to judge efficacy in subsequent preclinical 
therapeutic trials.
Methods
CRISPR/Cas9 production of PPT1 sheep. Two sgRNAs were designed and synthesised in order to target 
SpCas9 to the coding sequence for PPT1 R151 on chromosome 1 of the Ovis aries genome (sgRNA1 gagct-
ttctcctgggca and sgRNA2 agatgtgtgagctttctcct). A specific ssODN was designed for each of the two alternative 
guides (Supplementary Fig. 1), and sgRNA + ssODN + Cas9 mRNA were co-injected into the cytoplasm of sheep 
zygotes. At day 6–7 post injection blastocysts were surgically transferred to synchronous ewes as previously 
described18, resulting in 19 pregnancies. Genomic DNA was prepared from ear notches of each of 24 lambs. 
Genotyping was by PCR spanning the target site with primers F (ccaagacccaagaggtgaga) and R (gtgacagttccg-
catccttt) to give a 419 bp fragment that was then sequenced.
Analysis of autofluorescent storage material. Cervical, thoracic and lumbar portions of spinal cord 
were excised post mortem and fixed in formal saline for 10 days. Thereafter, tissues were transferred to a 50 mM 
tris, 0.05% azide buffer (pH7.6) for long term storage at 4 °C. Cervical spinal cord from homozygote and age- 
matched controls were trimmed sagittally into approximately 1 mm thick sections and mounted onto glass slides 
with vectashield fluorescent mounting medium (Dako). Autofluorescent storage material was visualized using a 
fluorescent microscope at X10 magnification (Leica DMLB microscope with Hammamatsu camera ORCA-ER 
attachment). Images were captured using Image J and Micromanager 1.4.18 software with a lumencore spectraX 
light source and GFP filter at excitation 485 nm and emission 520 nm.
PPT1 enzyme assay. Blood was collected by venipuncture. Heparin-treated blood was centrifuged in 
Vacutainers at 1000 × g for 15 min at 4 °C to isolate the plasma. Protein determination was carried on the plasma 
using micro BCA assay (Life technologies, UK). The 1 step PPT1 assay protocol was employed as described in4. 
Briefly, 20ug of plasma was added to 20ul of substrate solution (0.64 mM MU-6S-Palm ß Glc, 15 mM dithioth-
reitol (DTT), 0.375% (w/v) Triton X-100, and 0.1 ß glucosidase from almonds (Sigma) in McIlvain’s phosphate/
citrate buffer (pH 4.0). The reaction was incubated overnight (18–24 hours) at 37 °C and terminated by addition of 
0.5 M NaCO3/NaHCO3 (pH 10.7) containing 0.025% TritonX-100. Samples were read on a fluorometer at 405 nm 
(360 nm excitation and 460 nm emission).
Magnetic resonance imaging (MRI). Imaging subjects. Six animals (3 wild type and 3 homozygous 
mutants, M:F 2:1) were imaged at approximately 480 days. This time point was selected to provide the most 
animals in a specific 2 week period. In addition, this time point was similar to that used in another ovine study of 
naturally occurring CLN6 model (16 month)21.
Anaesthesia. The sheep was sedated with medetomidine (5µgkg-1; “Medetor”; Chanelle, Berkshire), ketamine 
(1mgkg-1; “Ketamidor”; Chanelle, Berkshire) and midazolam (0.25mgkg-1; “Hypnovel”, Roche, UK) which were 
combined and administered slowly “off the needle” into the jugular vein. Sternal recumbency developed over 
5 minutes. A jugular cannula was placed and anaesthesia induced with 3mgkg-1 IV propofol (“Propoven 1%”; 
Fresenius Kabi, Cheshire). Once unconscious, the trachea was intubated with an 8 mm endotracheal tube (ETT) 
and the cuff inflated. Anaesthesia was initially maintained using isoflurane (“IsoFlo”; Zoetis, Surrey) vaporized in 
oxygen (FiO2 > 0.95) administered via a Bain breathing system; the animals breathed spontaneously. Once in the 
scanner, the ETT was connected to a circle breathing system, and anaesthesia maintained with 1.5–2% isoflurane 
vaporized in 2 L/min oxygen. Mechanical ventilation was imposed using an MRI-compatible ventilator (Penlon 
200) to maintain normocapnia. Fractional concentrations of end-tidal carbon dioxide (Fe’CO2) were monitored 
continuously throughout scanning (lasting 40 minutes) but other physiological variables were assessed intermit-
tently because access was limited.
After scanning, isoflurane administration was ended, the sheep was removed from the scanner and posi-
tioned in sternal recumbency before IV atipamazole (25µgkg-1; “Antisedan”, Vetoquinol, Buckinghamshire) 
was administered. The animals continued to breathe 100% oxygen until active chewing/swallowing prompted 
tracheal extubation. The ETT was withdrawn with the cuff partially inflated in order to remove accumulated 
oropharyngeo-trachaeal fluid.
Image acquisition. MRI were acquired on a 1.5 T Philips Achieva (Philips, Best, The Netherlands) using a FlexS 
surface coil. Transverse T2-weighted (T2w) fast spin echo (FSE) images (TR = 5421 ms, TE = 100 ms, NSA = 4, 
slice thickness 3.85 mm, voxel size 0.41 × 0.41 mm, field of view 150 × 150 × 100 mm) were acquired, in addition 
to sagittal and dorsal imaging with comparable weighting and imaging parameters. Transverse FLAIR (fluid 
attenuated inversion recovery), and T1-weighted fast spin echo images were acquired before and after intravenous 
administration of gadopentetate dimeglumine (0.5 mmol/mL; “Magnevist”, Bayer, Berkshire).
Image analysis. Qualitative assessment was performed by an expert neuroradiologist with 11 years’ experi-
ence (GT). For quantitative volumetric analysis, an in-house pipeline was developed. Using SPM12 (Statistical 
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Parametric Mapping, The Wellcome Trust Centre for Neuroimaging, University College London, UK) with 
Matlab 2017a (MathWorks, Natick, MA, USA,) the transverse T2w images were up-sampled using linear interpo-
lation to high resolution isotropy, matching the through plane to the in-plane voxel size. The dorsal and sagittal 
images were linearly co-registered to this with 6 degrees of freedom using SPM12 to produce spatially-congruent, 
uniform, high resolution triplanar orthogonal images36–38. Matlab was used to estimate an isotropic image from 
these using wavelet-based fusion reconstructions39. Expert manual intracranial segmentations were performed 
on all three orthogonal planes of the T2w SE imaging, and the SPM (Statistical parametric mapping) linear trans-
forms were used to produce a high-resolution whole brain mask in isotropic space, binarized by thresholding at 
0.5. In the absence of a bespoke template and atlas for the specific breed used here the University of Melbourne 
Corriedale ovine atlas from Liyanage et al. was chosen, since this contained regions of interest (ROI) relevant 
to the expected areas of pathological brain involvement40. The Melbourne template does not include a T2w 
image, however, and a template including a brain-extracted T2w from INRA (Institut National de Recherche 
Agronomique, France) was chosen to improve accuracy of template-based segmentation41. The Melbourne 
template was warped into INRA T1w template space using ANTs (Advanced Normalization Tools, Penn Image 
Computing & Science Lab, University of Pennsylvania, USA) diffeomorphic registration with affine and SyN algo-
rithms, and cross correlation similarity metric40–43. The resultant series of transforms produced the Melbourne 
atlas regions of interest in INRA template space. Individual wavelet-reconstructed T2w high resolution isotropic 
images for each sheep were non-linearly warped into INRA T2w template space using ANTs. The inverse con-
catenation of the resulting linear transforms and nonlinear warps were used to produce native space Melbourne 
atlas segmentations for each subject using nearest neighbor interpolation. Each segmentation was individually 
reviewed for artefact and accuracy. Based on qualitative assessment, and given the sample size, comparisons 
were made between supraventricular cortex (bilateral motor cortex), tri-ventricular CSF, and the cerebellum atlas 
regions. Matlab was used to calculate ROI (Region of Interest) volumes for comparison. Each animal’s regional 
volumetric data was normalised to their individual intracranial volume and converted to a percentage to reduce 
variability44. With two male and one female animal in each group, the effect of sex was not examined; in prior 
work with a related naturally-occurring ovine model, sexual dimorphism was shown to contribute less to brain 
volume variance than that expected from pathological differences in affected sheep21.
Brain atrophy analysis. Brains were excised at post mortem with the pituitary gland detached (Fig. 3). Each 
brain was weighed and a photograph taken on Dispocut white boards (CellPath, UK). Statistical tests were per-
formed in GraphPad Prism software. For all analyses P < 0.005 were considered statistically significant.
Clinical observations. Weekly clinical assessment commenced once a phenotype was observed in the first 
homozygote sheep and was performed by veterinary clinicians including a certified or board-eligible veterinary 
neurologist, together with a board-eligible small ruminant specialist. Assessments included hands-off observa-
tion of mentation, behaviour, gait, balance, and navigation, followed by a general physical examination and full 
neurological examination as described by Crilly et al.20 (See Supplementary Fig. 2). In addition, objective scores 
of clinical abnormality (0–4; where 0 = normal and 4 = severe) were obtained for (i) deficits in vision and and 
subcortical processing of glare via the menace response and dazzle reflex45, respectively (after confirming that 
cranial nerve V and VII reflexes were intact), (ii) conscious proprioception via hoof placement, knuckling and 
hopping tests, (iii) body condition scoring, and (iv) spinal cord integrity via cutaneous trunci reflex testing. In 
accordance with UK Home Office regulations (IACUC equivalent) the CLN1 sheep were euthanised once those 
signs reached a humanely defined end point with age-matched controls euthanised in parallel with each homozy-
gote. The humanely defined end-point was selected prior to the development of any seizures in the CLN1 sheep 
therefore a “terminal” end-point may occur a few of months later than the humanely defined time point.
Ethics statement. All animal work was reviewed and approved by the Animal Welfare and Ethical Review 
Board (AWERB) at the Roslin Institute and conducted under the authority of the UK Home Office (equivalent 
of IACUC).
Data Availability
Material will be made available if appropriate requests are received.
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